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EDITORIAL
Estrogen: It’s not just for reproduction any more
Estrogens serve critical roles in the development of given estrogen may vary with different assay systems. For
female secondary sex characteristics and the regulation instance, while E2 facilitates endothelial cell angiogenesis
of uterine changes that occur during the menstrual cycle [2], another estrogen metabolite, 2-methoxyestradiol, in-
and pregnancy. In addition, a variety of tissues unrelated duces apoptosis in endothelial cells and is anti-angiogenic
to reproductive function contain estrogen-producing [3]. Both of these are “estrogen” effects. As another
aromatase activity. It is therefore not surprising that example, tamoxifen, recently found to have “anti-estro-
clinical data demonstrate beneficial effects of estrogen gen” effects in preventing breast cancer, may have “pro-
on osteoporosis and atherosclerosis in women. These estrogen” effects in decreasing the risk of cardiovascular
findings suggest that this hormone has important physio- disease [4]. Thus, the effects of estrogen depend upon
logical roles beyond those related to gonadal function. both its metabolism and its targets.
The potential spectrum of such actions has been ex- Several aspects of cellular physiology may explain how
tended by studies indicating that gender may influence similar—or even identical—forms of estrogen have var-
the outcome of progressive renal disease. This gender ied impacts on different biological systems. One of these
impact can be positive or negative, perhaps reflecting is the activation status of the target cell. We have ob-
the effects of several gonadal steroids on the varied path- served that endothelial cells respond differently to E2
ways for inflammation, cell migration or proliferation when they are in confluent cultures than when they are
that mediate different disease models. The experiments actively dividing, are injured or have been exposed to
reported by Silbiger and colleagues in this issue of Kid- stimulatory cytokines [5]. This variability would suggest
ney International continue their investigation of a poten- that ER activation serves largely to amplify other signal-
tial role for estrogen in regulating one aspect of this ing pathways that have been activated by concurrent
intricate pathophysiological web, mesangial cell collagen stimuli. In agreement with this proposed model, E2 en-
synthesis [1]. The authors show that estrogen increases hances endothelial cell-leukocyte adhesion in response
AP-1 transcription factor activity that in turn inhibits to tumor necrosis factor (TNF)a, but has no effect on
type I collagen gene activation. In order to consider the interleukin-1-stimulated adhesion or on adhesion in the
implications of these findings for glomerulosclerosis, it absence of TNFa [6]. Conversely, other investigators
is appropriate for us to review current understanding of have determined that the ability of basic fibroblast
estrogen receptor (ER) function. Much of the available growth factor (bFGF) to stimulate angiogenesis is abro-
data are derived from manipulating transformed cells. gated in ER-deficient mice [7]. The requirement for a
Only recently have investigators begun to examine non- functional ER in this model suggests that E2/ER acts as
transformed cells, and studies of cells from renal tissue a necessary, permissive cofactor for signals stimulated
are extremely rare. The present discussion will thus serve by other mediators. Consistent with this interpretation
largely as a guide for future studies related more directly is the observation that the ER forms a transcription
to ER function in the kidney. regulatory complex with the p300 transcription factor
Estrogen is known to interact with a cytoplasmic re- [8] that can be activated by growth factors.
ceptor that can dimerize, undergo phosphorylation and In addition to interaction with other signaling path-
be translocated to the nucleus where it acts as a transcrip- ways, estrogen effects may be determined by ER config-
tion factor; however, our concept of ER actions on tissue uration or type. Different estrogens may bind to recep-
function has become increasingly complex. Multiple tors that have been structurally modified by their milieu,
forms of estrogen exist. The most abundant circulating or may themselves modify the ER structure, forming
estrogen in humans is 17b-estradiol (E2). In many bio- transcription regulatory complexes with different affini-
assays, such as the ability to stimulate endometrial cell ties for gene-promoter sequences or for transcription co-
proliferation, E2 is the most active estrogen on a molar factors [9]. Splice variants of the ER, perhaps similarly
basis. However, the measured biological activity of a reflecting variations in the cellular milieu, have been de-
tected by reverse transcription-polymerase chain reaction
analysis of vascular smooth muscle cells [10]. WhetherKey words: hormone, aromatose activity, gender and progressive renal
disease, mesangial cell collagen. these variants are expressed at the protein level, or
whether expressed variants have unique biological prop- 1999 by the International Society of Nephrology
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erties, remains to be determined. Finally, the recent dis- notion that estrogen could play a significant regulatory
role. Future studies might address several importantcovery of a distinct gene for a second ER, termed ERb
[11], has stimulated intense interest in determining questions. First, the present studies were performed in
murine cells; since there may be significant species speci-whether different receptor gene products mediate differ-
ent estrogen effects on cells. ficity in regulation of gene transcription, confirmatory
studies in human tissue are important. Second, in manyA third determinant of estrogen effects may be “non-
genomic” mechanisms of ER action. In endothelial cells, diseases, glomerular accumulation of type IV collagen
is at least as important as that of type I collagen, if notmitogen-activated protein (MAP) kinase activation by
E2 is slow (3 hours) and is prevented by inhibitors of more so. Can the present results with type I collagen be
generalized to all forms of collagen? Third, the presentprotein synthesis, suggesting a classical action of ER on
gene transcription [12]. In contrast, MAP kinase activa- experiments evaluated “basal” collagen expression in
cultured cells. Will estrogen also decrease responses totion by E2 in breast cancer epithelia is virtually immedi-
ate and does not require new protein synthesis [13]. pathogenic stimuli? Finally, animal models will ulti-
mately determine the clinical significance of these find-Endothelial cells also may have non-genomic, ER-medi-
ated signaling pathways. For example, bFGF release (as ings. Thus, this report by Silbiger and colleagues provides
a welcome stimulus for additional characterization of aopposed to synthesis) by endothelial cells cultured on
basement membrane proteins is enhanced by ER activa- regulatory mechanism that is potentially important in
glomerulosclerosis.tion, but is not affected by inhibitors of protein synthesis
[14]. These data suggest that some ER-mediated signals
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